Index of drugs

Active immunization against yellow fever in people: traveling, passing or living in an endemic area; traveling to any country where an International Vaccination Certificate is required on entry (which may or may not depend on the previous itinerary); exposed to contact with potentially infectious materials (eg laboratory staff).

1 dose (0.5 ml) contains: not less than 1000 LD units₅₀ live attenuated yellow fever virus (strain 17 D-204).

Vaccine against yellow fever, alive. As with other live attenuated viral vaccines, specific subclinical infections in healthy vaccinated individuals result in specific T and B lymphocytes and specific antibodies are produced. Resistance occurs about 10 days after vaccination. International health regulations require revaccination every 10 years to update the certificate.

Hypersensitivity of any component of the vaccine, eggs or chicken proteins. Serious hypersensitivity reactions (eg anaphylaxis) after previous administration of a yellow fever vaccine. Immunodeficiency: congenital, idiopathic or due to systemic treatment with steroids (greater than routine doses of topical or inhaled steroids), radiotherapy or treatment with cytostatics. History of thymic dysfunction (including thymoma, thymic excision). Symptomatic HIV infection. Asymptomatic HIV infection, accompanied by signs of immune disorder. Children <6 months Disease with fever (vaccination should be postponed). Do not give intravascularly.

Before deciding whether to give a vaccine, you should consider whether you have an increased risk of having vaccine side effects. Patients ≥60 years of age have an increased risk of severe and life-threatening side effects (including YEL-AVD and YEL-AVD), so the vaccine should only be given to people who are particularly prone to developing yellow fever. Children from 6 to 9 months they should be vaccinated only in exceptional situations (eg during major epidemics) and on the basis of current official recommendations. In patients with transient immunodeficiency, vaccination should be postponed until immune function is improved; in patients receiving systemic corticosteroids for ≥14 days, it is advisable to postpone the vaccination at least 1 month after the end of treatment. There is currently insufficient data to determine the immunological parameters that distinguish HIV-infected people that can be safely vaccinated and that can produce protective levels of antibodies from those who could be both risky and ineffective, so if a person with an asymptomatic HIV can not escape If you travel to an endemic area, consider the potential risks and benefits of vaccination considering the available official recommendations. Children> 6 months old, born to HIV-positive mothers, may be vaccinated if it is confirmed that they are not infected with HIV, while those infected with HIV that potentially require protection against yellow fever should be referred to a specialist pediatric team in to determine the indication for vaccination. Patients with coagulation disorders (eg haemophilia or thrombocytopenia or those receiving anticoagulant therapy) should not be administered intramuscularly but subcutaneously. Do not give the vaccine to patients with hereditary fructose intolerance.

During pregnancy and breastfeeding, administer only if absolutely necessary and only after careful consideration of the risk / benefit ratio. There are very few reports suggesting that the yellow fever vaccine virus can be transmitted from mothers who have received a yellow fever vaccine in the postpartum period on an infant.After the transfer, the infant may experience a neurotrophic disease (YEL-AND), ended with the recovery of infants.

Very common: headache, reactions at the injection site (pain, redness, hematoma, induration, edema). Common: nausea, diarrhea, vomiting, muscle pain, fever, weakness. Uncommon: abdominal pain, arthralgia. In addition, there may be: lymphadenopathy, anaphylaxis, angioneurotic edema, a neurotrophic disease associated with yellow fever vaccine - YEL-AND (you may have high fever, muscle pain, headache and low blood pressure, which may turn into one or more of the the following symptoms: confusion, lethargy, encephalitis, encephalopathy and meningitis, several fatal cases, risk factors for YEL-AND include: congenital or acquired immunodeficiency, age> 60 years), seizures, Guillain-Barré syndrome, focal neurological deficits, rash, urticaria, visceral disease associated with vaccination against yellow fever - YEL-AVD (may manifest in fever, fatigue, muscle pain, headache and hypotension, with the possibility of developing one or more of the following: metabolic acidosis, disintegration muscle and liver cells, lymphopenia and monkey incapacity, renal failure and respiratory failure, several cases fatal; YEL-AVD risk factors include: thymic disease, age> 60 years).

Subcutaneously or intramuscularly. Intramuscular administration - in the anterior part of the thigh in infants or small children (from 6 months to 2 years) or the shoulder muscle in older children and adults, can be done if it is in accordance with the relevant official recommendations.Basic vaccination: adults and children from 9 months: 1 dose (0.5 ml) at least 10 days before arrival in the endemic area; 6-9 months old children: only in exceptional situations and on the basis of current official recommendations, in which case the dose is the same as in older children and adults. People> 60 years old: only if there is a significant and unavoidable risk of getting a yellow fever, the dose is the same as for adults.Revaccination: 1 dose (0.5 ml) after 10 years in people who are considered exposed to exposure.